ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Evolocumab in Primary Prevention." 🧬🛡️🎯 LDL: Down 55%. CV Events: Down 25%."
Episode Synopsis
🚀 VESALIUS-CV delivers powerful evidence: in high-risk patients without prior MI or stroke, evolocumab significantly reduced 3-point MACE by 25% and 4-point MACE by 19%, with LDL-C lowered to a median of 45 mg/dL. 💡 These results expand the horizon of prevention, showing that deep LDL reduction is both safe and effective in averting first cardiovascular events. 🫀 Strong science. Clear signal. A new chapter in preventive cardiology. #Cardiology #LDL #Prevention #VESALIUSCV
In God we trust